



STAR PHARMACEUTICAL LIMITED
(Company Registration No. 200500429W)
(Incorporated in Singapore)

PROFIT GUIDANCE

The Board of Directors (“**Board**”) of STAR Pharmaceutical Limited (“**Company**”, and together with its subsidiaries, collectively “**Group**”) wishes to announce that after preliminary assessment of the Group’s draft unaudited financial results for the half year ended 30 June 2019 (“**1H2019**”), the Board would like to advise that the Group is expected to report an operating loss for 1H2019.

The significant drop in an operating loss for 1H2019 was mainly attributed to lower sales and lower profit margins of drugs during the second quarter of 2019.

Further details of the Group’s financial performance will be disclosed when the Company finalises and announces its unaudited financial results for 1H2019 on or before 14 August 2019.

In the meantime, shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company and to seek the advice of stockbrokers, bankers or financial advisers when dealing in the shares of the Company.

BY ORDER OF THE BOARD

Xu Zhi Bin
Executive Chairman
18 July 2019